Oraverse Injection, Solution
Product Images NDC 0362-0101

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Oraverse (NDC 0362-0101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Septodont, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 0362 0101 10

FDA Label Image

Chemical Structure (Oraverse 01)

FDA Label Image

Figure 1 (Oraverse 02)

This is a statistical analysis of the proportion of patients with normal sensation, divided into two groups: Control and Oraverse. The median time for the control group was 155 minutes for 122 patients, while for the Oraverse group, it was 70 minutes for the same number of patients. The Stratified log-rank p-value obtained was less than 0.0001, indicating that there is a significant difference between the two groups. The graph shows the proportion of censored patients at different time intervals.*

FDA Label Image

Figure 2 (Oraverse 03)

This text represents a graph showing the proportion of patients with normal sensation over time. The graph compares two groups: a control group and a group treated with OraVerse. The median time for the control group to achieve normal sensation was 132.5 minutes, while the median time for the OraVerse group was 50 minutes. The graph also shows that the stratified log-rank p-value was less than 0.0001, indicating a significant difference between the two groups. The time scale on the graph ranges from 0 to 300 minutes.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.